This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

In ADM's Bio-Bailout, Red Flags for Recent IPO Darlings

Stocks in this article: ADMTOTDOWCVXMBLXSZYMKIOR

NEW YORK ( TheStreet) -- Fortunes shift quickly for IPO darlings, and that's been the case with bioproducts companies that successfully went public in the past two years. Their stocks have crashed, in some cases, spectacularly so.

Now, an announcement from Archer Daniels Midland (ADM) that it's bailing out of a bioplastics joint venture -- it was going to use ADM agricultural feedstock to make bioplastics that would replace petrochemical products -- highlights that it's not just the stock values of bioproducts plays that can falter, but the funding and support for small bio companies from big balance sheet partners.

That's a red flag that has always been inherent in making a bet on the bioproducts class, but as of yet, hadn't been exposed in a publicly traded bioproducts company.

Shares of ADM's jilted bioplastics partner Metabolix (MBLX) fell by 55% on Friday -- the termination of the joint venture was announced after the close on Thursday.

Shares of other recent bioproducts IPOs weren't impacted by the ADM bailout, but these companies have all fallen far from their IPO prices already. KiOR (KIOR) is down 34% since its 2011 IPO. Gevo (GEVO) is down 65% since its 2011 IPO. Amyris (AMRS), down 35% since its Oct. 2010 IPO. Solazyme (SYZM), down 48% since its June 2011 public offering.

All of these bioproducts IPOs had one trading theme in common: They were great for a deal flip, and that's about it. Shares of each of these stocks went higher immediately after the IPO pricing, only to eventually fall to an even greater degree than they rose , and they are still years from sustainable revenues and proven large-scale commercialization.

There are between 10 and 12 bioproducts companies still in the IPO pipeline at the start of 2012, but given the performance of the most recent offerings, it is hard to imagine a big crop of bio-IPOs making it this year.

ADM has now given investors another reason to be wary of Wall Street's efforts to take these companies public.

"I think it is relevant to all deals. I think there will be a lot more scrutiny of the 10-12 deals filed in this space right now," said Stifel analyst Jeff Osborne.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs